Journal article
HER2 testing in a population-based study of patients with metastatic breast cancer treated with trastuzumab.
Abstract
CONTEXT: The development of trastuzumab has led to new therapeutic strategies for patients with breast cancer. Trastuzumab has been shown to only be effective in those patients whose cancers are HER2 positive by either immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH).
OBJECTIVE: To determine the accuracy of HER2 testing in 2 provinces in Canada.
Authors
O'Malley FP; Thomson T; Julian J; Have C; Cosby R; Gelmon K; Andrulis I; Whelan T
Journal
Archives of Pathology & Laboratory Medicine, Vol. 132, No. 1, pp. 61–65
Publisher
Archives of Pathology and Laboratory Medicine
Publication Date
January 1, 2008
DOI
10.5858/2008-132-61-htiaps
ISSN
0003-9985